RRML - Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- July 2022 -
 
Normality assessment, few para... 6
The role of cytokines, cytogen... 4
The Effect of Resveratrol on S... 3
Approaching Risk Management in... 3
WWP1, TGF β and KLF5 gene exp... 2
Anticoagulant mechanisms are m... 2
Angiotensin-converting enzyme ... 2
Severe adverse reactions to bl... 2
Case report – rare type of a... 2
Impact of preanalytical variab... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Ahead of print DOI:10.2478/rrlm-2022-0026
XML
TXT

Research article

Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis

Yan Xu, Xianqiu Yu, Xinlong Zhang

Correspondence should be addressed to: Xinlong Zhang

Abstract:

Background: To study the expressions of transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in patients with acute myeloid leukemia (AML) and their values for prognosis. Methods: A total of 120 AML patients treated from January 2015 to December 2018 were selected. Bone marrow mononuclear cells were isolated. The expressions of TGF-β1 and VEGF were detected by RT-PCR, and their associations with clinical characteristics were analyzed. The overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The risk factors for prognosis were analyzed through the Cox proportional hazards model. Results: The AML group had significantly lower relative expression of TGF-β1 and higher relative expression of VEGF than those of the control group (P<0.05). TGF-β1 and VEGF levels were significantly correlated with white blood cell count, hemoglobin, platelets, and peripheral blood juvenile cells (P<0.05). TGF-β1 level was higher and VEGF level was lower in the patients with complete response than those in the patients with partial response and no response (P<0.05). Both OS and DFS of the patients with high TGF-β1 expression were better than those of the patients with low TGF-β1 expression, while they were also superior among the patients with low VEGF expression (P<0.05). Platelets, TGF-β1 and VEGF were independent influencing factors for OS, and white blood cells, TGF-β1 and VEGF were independent influencing factors for DFS (P<0.05). Conclusions: AML patients have decreased expression of TGF-β1 and increased expression of VEGF, and such changes are closely associated with the prognosis of AML.

Keywords: TGF-β1, VEGF, acute myeloid leukemia, prognosis

Received: 26.11.2021
Accepted: 6.6.2022
Published: 14.6.2022

 
  PDF Download full text PDF
(871 KB)